pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,855 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT824Endpoints627BioPharma Dive239onclive165Fierce Biotech91BioSpace90raps32globenewswire health28fda press
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology
  • Eli Lilly issues data sharing ultimatum to 340B hospitals
    Select hospitals have refused to share data to prove they’re not double-dipping drug discounts, Lilly said. Hospitals, which have until Monday to comply, are urging the government to intervene.
    BioPharma Dive · 1mo ago↗ source
  • STAT+: Longevity startup NewLimit raises $435 million ahead of first clinical trial
    Longevity startup NewLimit plans to launch its first clinical trial of a liver medicine after raising a staggering $435 million in new funding.
    STAT · 1mo ago↗ source
  • Fulcrum exploring a potential sale after FDA sidelined its sickle cell drug
    Fulcrum’s setback is the latest in a series of stumbles for the developers of sickle cell medicines, among them Pfizer, Novartis and Intellia Therapeutics.
← prev
page 41 of 75
next →
21
fda recalls20
fda medwatch17
6
Hematology6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
BioPharma Dive · 1mo ago
↗ source
  • What’s next for VEGF? #ASCO26 offered clues, but answers will have to wait
    CHICAGO — Not long ago, there were hopes that a new class of cancer drugs would repeat the success of Keytruda. Instead, it seems more likely they could end up making up for its weaknesses. Many ...
    Endpoints · 1mo ago↗ source
  • STAT+: Radiopharmaceutical shows promise in post-Pluvicto setting
    Abivax's ulcerative colitis data, Fulcrum's scrapped sickle cell drug, and more biotech news from The Readout
    STAT · 1mo ago↗ source
  • Male contraception startup closes $92.5M Series B; Novartis bets on actinium
    💸 Funding male contraception: Contraline closed a $92.5 million Series B financing to support a Phase 3 study of a male contraceptive dubbed NES/T. The daily treatment is a gel rubbed on the shoul…
    Endpoints · 1mo ago↗ source
  • Travere pays Everest $112M upfront to grow rare kidney disease pipeline
    Travere Therapeutics is enlisting the help of China-based Everest Medicines to bolster its rare kidney disease pipeline beyond its approved medicine Filspari. The San Diego biotech is doling out $1…
    Endpoints · 1mo ago↗ source
  • Legend Biotech shares first in vivo CAR-T data, its next act after Carvykti
    Legend Biotech’s long-awaited first showing of in vivo CAR-T data is here, fueling momentum in the growing field. Legend reported results Tuesday on 12 lymphoma patients from an investigator-initia…
    Endpoints · 1mo ago↗ source
  • STAT+: Pharmalittle: We’re reading about a Lilly threat to 340B hospitals, Ebola vaccine funding, and more
    Lilly gave hospitals participating in a federal drug discount program five days to submit claims data or it will stop the price breaks
    STAT · 1mo ago↗ source
  • AbiVax falls as safety worries cloud ‘landmark’ immune drug results
    A handful of cancer cases reported among treatment recipients overshadowed efficacy results analysts described as “best-in-disease” and sent shares down more than 30%.
    BioPharma Dive · 1mo ago↗ source
  • How one state’s medical meal program lowered health care costs
    Medicaid work requirements, fast-tracked funding for experimental Ebola vaccines, and more health news from Morning Rounds
    STAT · 1mo ago↗ source
  • #ASCO26: Celcuity plans another FDA filing after positive breast cancer readout
    Celcuity said a combination regimen with its experimental drug gedatolisib doubled patients' likelihood of survival without disease progression or death in a late-stage breast cancer trial. Executi…
    Endpoints · 1mo ago↗ source
  • Citing 'dangerous deals,' lawmakers propose China restrictions
    A bipartisan group of Michigan lawmakers released a new bill that could greatly stifle the booming cross-border deals spree between Chinese and American biotechs. Rep. John Moolenaar (R-MI) and Rep…
    Endpoints · 1mo ago↗ source
  • #ASCO26: Roche details narrow failure of breast cancer pill trial
    Back in March, Roche revealed that the breast cancer pill on which it had pinned billion-dollar sales expectations had failed in a pivotal Phase 3 trial. Data presented Tuesday at ASCO reveal ...
    Endpoints · 1mo ago↗ source
  • Fulcrum ends sickle cell ambitions following regulatory feedback, will seek exit
    Fulcrum Therapeutics is scrapping its sole clinical-stage medicine after feedback from the FDA that referenced a recently pulled cancer drug from Ipsen. Fulcrum had planned to enter a registrationa…
    Endpoints · 1mo ago↗ source
  • Cancer cases weigh down Abivax’s Phase 3 maintenance data in ulcerative colitis
    Abivax has proclaimed that its maintenance trial in ulcerative colitis delivered “landmark” results, and the drug's safety profile has previously been one of its main potential selling points. But…
    Endpoints · 1mo ago↗ source
  • Praxis sinks on late-stage study fail for seizure pill, halts second trial
    Praxis Precision Medicines has had a decent run over the past eight months or so, with two major clinical wins. But on Monday, the company disclosed a late-stage failure for its investigational sei…
    Endpoints · 1mo ago↗ source
  • ASCO ‘26: Bispecifics vs. ADCs, a ‘RAS’ revolution and a step change in prostate cancer
    At the year’s biggest cancer meeting, a high-stakes clash between two popular drug classes erupted, and scientists made headway against a once-insurmountable foe.
    BioPharma Dive · 1mo ago↗ source
  • Obesity care startup Ilant Health raises $15M
    Ilant Health has raised $15 million in a Series A funding round to expand its personalized approach to treating obesity. Ilant is one of many virtual care companies competing to help employers and…
    Endpoints · 1mo ago↗ source
  • Why US-manufactured pharmaceutical packaging equipment matters
    As manufacturers modernize operations, the origin of their equipment is a strategic consideration.
    BioPharma Dive · 1mo ago↗ source
  • Updated: Allen Institute launches $400M effort to turn brain atlas lessons into medicines
    A Seattle-based nonprofit known for basic brain research is launching a $400 million initiative to translate its knowledge into drug development for neurodegenerative diseases, including Alzheimer'…
    Endpoints · 1mo ago↗ source
  • Opinion: The virtual end of the doctor’s office waiting room
    It’s time to rethink and redesign how patients enter the health care system altogether, writes emergency physician Iyesatta Massaquoi Emeli.
    STAT · 1mo ago↗ source
  • STAT+: Online care is caught in the crossfire as states crack down on corporate medicine
    Growing legislative scrutiny across multiple states targets the corporate structure underlying most direct-to-consumer telehealth businesses.
    STAT · 1mo ago↗ source
  • STAT+: Trump administration releases rules for new Medicaid work requirements
    States are racing to implement the new requirements by the start of next year.
    STAT · 1mo ago↗ source
  • STAT+: Eli Lilly warns hospitals to submit claims data in the next five days or lose their 340B drug discounts
    Eli Lilly has told more than 1,000 hospitals participating in the 340B drug discount program to submit claims data over the next five days — or lose price breaks.
    STAT · 1mo ago↗ source